Celebrex News and Research

RSS

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

Painkiller warning for heart patients: Study

According to the latest study, taking some commonly prescribed painkillers for even a short while might increase the risk of dying from a heart attack or stroke. The study also reports that when heart attack survivors took the drugs for as little as a week, it appeared to boost their risk of another heart attack, stroke or sudden death. The results, published in Circulation, a journal of the American Heart Association, surprised even the researchers.

10 May 2011

Protecting skin from sun's ultraviolet radiation is best way to avoid potential skin problems

Summertime means plenty of fun in the sun for many. "I would burn on Saturday and Sunday, peel by Wednesday and be back on the water by the next Saturday doing the same thing," says Thomas Randall, a man in his 70s who spent much of his youth at a lake or a beach trying to tan a pale complexion. But countless hours of sun exposure have taken a toll on his skin, and he now needs regular examinations to search for pre-cancerous moles.

7 Apr 2011

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx, Bextra, and Avandia.

22 Feb 2011

Arthritis drug reduces incidence of non-melanoma skin cancers

A widely-used arthritis drug reduces the incidence of non-melanoma skin cancers - the most common cancers in humans - according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib (brand name Celebrex), which is currently approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain in adults led to a 62 percent reduction in non-melanoma skin cancers, which includes basal cell carcinomas and squamous cell carcinomas.

3 Dec 2010

NSAID Celebrex may help prevent non-melanoma skin cancer development: Research

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.

30 Nov 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

Policy restrictions for certain medications lead to decreased drug use and substantial savings for insurers

Policies that restrict reimbursement for certain medications can save money for health insurers without driving patients to seek other kinds of health care, a new review of studies suggests.

19 Aug 2010

New method to synthesize drug candidates for testing

Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.

25 Jun 2010

International study to test effectiveness of celecoxib in preventing growth of precancerous polyps

Rush University Medical Center is testing whether celecoxib, known by its brand name Celebrex, can help prevent the growth of precancerous polyps that form in the colon, rectum and small intestine of children with an inheritable genetic disease called familial adenomatous polyposis.

14 May 2010

Anti-inflammatory prescription drug reduces the risk of common skin cancer in humans

A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine.

5 Jan 2010

New chemoprevention therapy for skin cancer

People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon.

5 Jan 2010

Senate rejects mass importation of medicine from Canada

In the midst of President Obama's push for health care reform, the Senate rejected a plan to allow American pharmacies and drug wholesalers to import federally approved drugs from abroad. That vote has proved to be a headache for customer service staff at companies like Canadameds.com (http://www.Canadameds.com), which sells low-cost prescription drugs directly to American consumers.

24 Dec 2009

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

24 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

With his proposed health care reform plan, President Barack Obama has set his sights on cutting name-brand prescription drug costs by 50 percent for Medicare patients who fall into the "Part D" coverage gap, universally known as the "donut hole." Plan advocates rave about the potential cost-cutting and feel it's a promising start to health care reform.

7 Nov 2009

Four percent annual growth for chronic pain drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).

23 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

Discovery in colon cancer prevention

A new study finds that individuals who have low expression of the "Celebrex gene," 15-PGDH, are actually resistant to Celebrex treatment when used to prevent colon cancer.

18 May 2009

Pfizer to give away 70 of its most widely prescribed drugs to those who lost jobs

Pfizer on Thursday announced a new program that would provide some of its existing customers access to more than 70 types of medications at no cost if they have recently been laid off or lost their prescription drug coverage, USA Today reports. The program -- called MAINTAIN, or Medicines Assistance for Those who Are in Need -- will begin July 1.

15 May 2009

New findings on COX-2 inhibitor side effects

In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.

29 Apr 2009